Loading…

Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects

Vaccines impact antibiotic-resistant infections in two ways: through a direct reduction in the organisms and strains carrying resistant genes that are specifically targeted by the vaccine and also via a secondary effect through a reduction in febrile illnesses that often lead to the use of antibioti...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings of the National Academy of Sciences - PNAS 2018-12, Vol.115 (51), p.12896-12901
Main Authors: Klugman, Keith P., Black, Steven
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c509t-f9c089fc3a47918931e764725d0fa3e9692e78f1a022ab96f90382f83ce2802d3
cites cdi_FETCH-LOGICAL-c509t-f9c089fc3a47918931e764725d0fa3e9692e78f1a022ab96f90382f83ce2802d3
container_end_page 12901
container_issue 51
container_start_page 12896
container_title Proceedings of the National Academy of Sciences - PNAS
container_volume 115
creator Klugman, Keith P.
Black, Steven
description Vaccines impact antibiotic-resistant infections in two ways: through a direct reduction in the organisms and strains carrying resistant genes that are specifically targeted by the vaccine and also via a secondary effect through a reduction in febrile illnesses that often lead to the use of antibiotics. We review here the impact of pneumococcal conjugate vaccines (PCVs) on the prevalence of antibiotic-resistant disease and antibiotic usage as an example of the direct effect of vaccines on antibiotic resistance and the impact of influenza vaccination on antibiotic usage as an example of a secondary effect. A prelicensure study of a PCV in Africa demonstrated 67% fewer penicillin-resistant invasive disease episodes in the PCV group compared with controls. Similar studies in the United States and Europe demonstrated reductions in antibiotic use consistent with the vaccines’ impact on the risk of otitis media infections in children. Postlicensure reductions in the circulation of antibiotic-resistant strains targeted by the vaccines have been dramatic, with virtual elimination of these strains in children following vaccine introduction. In terms of a secondary effect, following influenza vaccination reductions of 13–50% have been observed in the use of antibiotics by individuals receiving influenza vaccine compared with controls. With the demonstrated effectiveness of vaccination programs in impacting the risk of antibiotic-resistant infections and the increasing threat to public health that these infections represent, more attention needs to be given to development and utilization of vaccines to address antibiotic resistance.
doi_str_mv 10.1073/pnas.1721095115
format article
fullrecord <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6304973</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>26574194</jstor_id><sourcerecordid>26574194</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-f9c089fc3a47918931e764725d0fa3e9692e78f1a022ab96f90382f83ce2802d3</originalsourceid><addsrcrecordid>eNpdkctLAzEQxoMoWh9nT8qCFy9rJ8lmkxwURHyB4EXPIU0TTWmTmuyK_vemtNbHaYaZ33x8w4fQIYYzDJwO50HnM8wJBskwZhtoUDpct42ETTQAILwWDWl20G7OE4BCCdhGOxQYk1iyATq_n8216aroKvvhc-fDS_WujfHB5sqHKtlxbxZDHTo_8rHzpsxyIXUwdh9tOT3N9mBV99DzzfXT1V398Hh7f3X5UBsGsqudNCCkM1Q3XGIhKba8bThhY3CaWtlKYrlwWAMheiRbJ4EK4gQ1lgggY7qHLpa68340s2NjQ5f0VM2Tn-n0qaL26u8m-Ff1Et9VS6GRnBaB05VAim-9zZ2a-WzsdKqDjX1WBDNBijlKCnryD53EPoXyXqFa4JhLAoUaLimTYs7JurUZDGoRjVpEo36iKRfHv39Y899ZFOBoCUxyF9N6T1rGGywb-gW6JZOJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2160717920</pqid></control><display><type>article</type><title>Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects</title><source>JSTOR Archival Journals and Primary Sources Collection【Remote access available】</source><source>PubMed Central</source><creator>Klugman, Keith P. ; Black, Steven</creator><creatorcontrib>Klugman, Keith P. ; Black, Steven</creatorcontrib><description>Vaccines impact antibiotic-resistant infections in two ways: through a direct reduction in the organisms and strains carrying resistant genes that are specifically targeted by the vaccine and also via a secondary effect through a reduction in febrile illnesses that often lead to the use of antibiotics. We review here the impact of pneumococcal conjugate vaccines (PCVs) on the prevalence of antibiotic-resistant disease and antibiotic usage as an example of the direct effect of vaccines on antibiotic resistance and the impact of influenza vaccination on antibiotic usage as an example of a secondary effect. A prelicensure study of a PCV in Africa demonstrated 67% fewer penicillin-resistant invasive disease episodes in the PCV group compared with controls. Similar studies in the United States and Europe demonstrated reductions in antibiotic use consistent with the vaccines’ impact on the risk of otitis media infections in children. Postlicensure reductions in the circulation of antibiotic-resistant strains targeted by the vaccines have been dramatic, with virtual elimination of these strains in children following vaccine introduction. In terms of a secondary effect, following influenza vaccination reductions of 13–50% have been observed in the use of antibiotics by individuals receiving influenza vaccine compared with controls. With the demonstrated effectiveness of vaccination programs in impacting the risk of antibiotic-resistant infections and the increasing threat to public health that these infections represent, more attention needs to be given to development and utilization of vaccines to address antibiotic resistance.</description><identifier>ISSN: 0027-8424</identifier><identifier>EISSN: 1091-6490</identifier><identifier>DOI: 10.1073/pnas.1721095115</identifier><identifier>PMID: 30559195</identifier><language>eng</language><publisher>United States: National Academy of Sciences</publisher><subject>Antibiotic resistance ; Antibiotics ; Bacterial infections ; Bacterial Infections - epidemiology ; Bacterial Infections - prevention &amp; control ; Biological Sciences ; Children ; Direct reduction ; Disease control ; Drug resistance ; Drug Resistance, Bacterial - drug effects ; Humans ; Illnesses ; Influenza ; Influenza Vaccines - therapeutic use ; Medical technology ; Otitis media ; Penicillin ; Pneumococcal Infections - epidemiology ; Pneumococcal Infections - prevention &amp; control ; Pneumococcal Vaccines - therapeutic use ; Public health ; Side effects ; South Africa - epidemiology ; SPECIAL FEATURE: PERSPECTIVE ; Strains (organisms) ; Vaccines</subject><ispartof>Proceedings of the National Academy of Sciences - PNAS, 2018-12, Vol.115 (51), p.12896-12901</ispartof><rights>Volumes 1–89 and 106–115, copyright as a collective work only; author(s) retains copyright to individual articles</rights><rights>Copyright National Academy of Sciences Dec 18, 2018</rights><rights>2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-f9c089fc3a47918931e764725d0fa3e9692e78f1a022ab96f90382f83ce2802d3</citedby><cites>FETCH-LOGICAL-c509t-f9c089fc3a47918931e764725d0fa3e9692e78f1a022ab96f90382f83ce2802d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/26574194$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/26574194$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792,58237,58470</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30559195$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Klugman, Keith P.</creatorcontrib><creatorcontrib>Black, Steven</creatorcontrib><title>Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects</title><title>Proceedings of the National Academy of Sciences - PNAS</title><addtitle>Proc Natl Acad Sci U S A</addtitle><description>Vaccines impact antibiotic-resistant infections in two ways: through a direct reduction in the organisms and strains carrying resistant genes that are specifically targeted by the vaccine and also via a secondary effect through a reduction in febrile illnesses that often lead to the use of antibiotics. We review here the impact of pneumococcal conjugate vaccines (PCVs) on the prevalence of antibiotic-resistant disease and antibiotic usage as an example of the direct effect of vaccines on antibiotic resistance and the impact of influenza vaccination on antibiotic usage as an example of a secondary effect. A prelicensure study of a PCV in Africa demonstrated 67% fewer penicillin-resistant invasive disease episodes in the PCV group compared with controls. Similar studies in the United States and Europe demonstrated reductions in antibiotic use consistent with the vaccines’ impact on the risk of otitis media infections in children. Postlicensure reductions in the circulation of antibiotic-resistant strains targeted by the vaccines have been dramatic, with virtual elimination of these strains in children following vaccine introduction. In terms of a secondary effect, following influenza vaccination reductions of 13–50% have been observed in the use of antibiotics by individuals receiving influenza vaccine compared with controls. With the demonstrated effectiveness of vaccination programs in impacting the risk of antibiotic-resistant infections and the increasing threat to public health that these infections represent, more attention needs to be given to development and utilization of vaccines to address antibiotic resistance.</description><subject>Antibiotic resistance</subject><subject>Antibiotics</subject><subject>Bacterial infections</subject><subject>Bacterial Infections - epidemiology</subject><subject>Bacterial Infections - prevention &amp; control</subject><subject>Biological Sciences</subject><subject>Children</subject><subject>Direct reduction</subject><subject>Disease control</subject><subject>Drug resistance</subject><subject>Drug Resistance, Bacterial - drug effects</subject><subject>Humans</subject><subject>Illnesses</subject><subject>Influenza</subject><subject>Influenza Vaccines - therapeutic use</subject><subject>Medical technology</subject><subject>Otitis media</subject><subject>Penicillin</subject><subject>Pneumococcal Infections - epidemiology</subject><subject>Pneumococcal Infections - prevention &amp; control</subject><subject>Pneumococcal Vaccines - therapeutic use</subject><subject>Public health</subject><subject>Side effects</subject><subject>South Africa - epidemiology</subject><subject>SPECIAL FEATURE: PERSPECTIVE</subject><subject>Strains (organisms)</subject><subject>Vaccines</subject><issn>0027-8424</issn><issn>1091-6490</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdkctLAzEQxoMoWh9nT8qCFy9rJ8lmkxwURHyB4EXPIU0TTWmTmuyK_vemtNbHaYaZ33x8w4fQIYYzDJwO50HnM8wJBskwZhtoUDpct42ETTQAILwWDWl20G7OE4BCCdhGOxQYk1iyATq_n8216aroKvvhc-fDS_WujfHB5sqHKtlxbxZDHTo_8rHzpsxyIXUwdh9tOT3N9mBV99DzzfXT1V398Hh7f3X5UBsGsqudNCCkM1Q3XGIhKba8bThhY3CaWtlKYrlwWAMheiRbJ4EK4gQ1lgggY7qHLpa68340s2NjQ5f0VM2Tn-n0qaL26u8m-Ff1Et9VS6GRnBaB05VAim-9zZ2a-WzsdKqDjX1WBDNBijlKCnryD53EPoXyXqFa4JhLAoUaLimTYs7JurUZDGoRjVpEo36iKRfHv39Y899ZFOBoCUxyF9N6T1rGGywb-gW6JZOJ</recordid><startdate>20181218</startdate><enddate>20181218</enddate><creator>Klugman, Keith P.</creator><creator>Black, Steven</creator><general>National Academy of Sciences</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20181218</creationdate><title>Impact of existing vaccines in reducing antibiotic resistance</title><author>Klugman, Keith P. ; Black, Steven</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-f9c089fc3a47918931e764725d0fa3e9692e78f1a022ab96f90382f83ce2802d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antibiotic resistance</topic><topic>Antibiotics</topic><topic>Bacterial infections</topic><topic>Bacterial Infections - epidemiology</topic><topic>Bacterial Infections - prevention &amp; control</topic><topic>Biological Sciences</topic><topic>Children</topic><topic>Direct reduction</topic><topic>Disease control</topic><topic>Drug resistance</topic><topic>Drug Resistance, Bacterial - drug effects</topic><topic>Humans</topic><topic>Illnesses</topic><topic>Influenza</topic><topic>Influenza Vaccines - therapeutic use</topic><topic>Medical technology</topic><topic>Otitis media</topic><topic>Penicillin</topic><topic>Pneumococcal Infections - epidemiology</topic><topic>Pneumococcal Infections - prevention &amp; control</topic><topic>Pneumococcal Vaccines - therapeutic use</topic><topic>Public health</topic><topic>Side effects</topic><topic>South Africa - epidemiology</topic><topic>SPECIAL FEATURE: PERSPECTIVE</topic><topic>Strains (organisms)</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Klugman, Keith P.</creatorcontrib><creatorcontrib>Black, Steven</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Klugman, Keith P.</au><au>Black, Steven</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects</atitle><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle><addtitle>Proc Natl Acad Sci U S A</addtitle><date>2018-12-18</date><risdate>2018</risdate><volume>115</volume><issue>51</issue><spage>12896</spage><epage>12901</epage><pages>12896-12901</pages><issn>0027-8424</issn><eissn>1091-6490</eissn><abstract>Vaccines impact antibiotic-resistant infections in two ways: through a direct reduction in the organisms and strains carrying resistant genes that are specifically targeted by the vaccine and also via a secondary effect through a reduction in febrile illnesses that often lead to the use of antibiotics. We review here the impact of pneumococcal conjugate vaccines (PCVs) on the prevalence of antibiotic-resistant disease and antibiotic usage as an example of the direct effect of vaccines on antibiotic resistance and the impact of influenza vaccination on antibiotic usage as an example of a secondary effect. A prelicensure study of a PCV in Africa demonstrated 67% fewer penicillin-resistant invasive disease episodes in the PCV group compared with controls. Similar studies in the United States and Europe demonstrated reductions in antibiotic use consistent with the vaccines’ impact on the risk of otitis media infections in children. Postlicensure reductions in the circulation of antibiotic-resistant strains targeted by the vaccines have been dramatic, with virtual elimination of these strains in children following vaccine introduction. In terms of a secondary effect, following influenza vaccination reductions of 13–50% have been observed in the use of antibiotics by individuals receiving influenza vaccine compared with controls. With the demonstrated effectiveness of vaccination programs in impacting the risk of antibiotic-resistant infections and the increasing threat to public health that these infections represent, more attention needs to be given to development and utilization of vaccines to address antibiotic resistance.</abstract><cop>United States</cop><pub>National Academy of Sciences</pub><pmid>30559195</pmid><doi>10.1073/pnas.1721095115</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0027-8424
ispartof Proceedings of the National Academy of Sciences - PNAS, 2018-12, Vol.115 (51), p.12896-12901
issn 0027-8424
1091-6490
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6304973
source JSTOR Archival Journals and Primary Sources Collection【Remote access available】; PubMed Central
subjects Antibiotic resistance
Antibiotics
Bacterial infections
Bacterial Infections - epidemiology
Bacterial Infections - prevention & control
Biological Sciences
Children
Direct reduction
Disease control
Drug resistance
Drug Resistance, Bacterial - drug effects
Humans
Illnesses
Influenza
Influenza Vaccines - therapeutic use
Medical technology
Otitis media
Penicillin
Pneumococcal Infections - epidemiology
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines - therapeutic use
Public health
Side effects
South Africa - epidemiology
SPECIAL FEATURE: PERSPECTIVE
Strains (organisms)
Vaccines
title Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T02%3A52%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20existing%20vaccines%20in%20reducing%20antibiotic%20resistance:%20Primary%20and%20secondary%20effects&rft.jtitle=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20-%20PNAS&rft.au=Klugman,%20Keith%20P.&rft.date=2018-12-18&rft.volume=115&rft.issue=51&rft.spage=12896&rft.epage=12901&rft.pages=12896-12901&rft.issn=0027-8424&rft.eissn=1091-6490&rft_id=info:doi/10.1073/pnas.1721095115&rft_dat=%3Cjstor_pubme%3E26574194%3C/jstor_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c509t-f9c089fc3a47918931e764725d0fa3e9692e78f1a022ab96f90382f83ce2802d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2160717920&rft_id=info:pmid/30559195&rft_jstor_id=26574194&rfr_iscdi=true